Aldeyra Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Aldeyra Therapeutics, Inc. on March 11, 2015. The report discloses executive compensation awards granted by the Compensation Committee of the Board of Directors for performance during the twelve-month period ending December 31, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific executive bonus payments.
Material Changes
The material event reported is the awarding of performance bonuses to three executive officers. There are no reported changes to the company's financial position or operations in this document.
Management Commentary and Risks
The filing contains no management outlook, guidance, risk factors, or discussion of contingencies. It strictly reports the execution of the 2014 performance bonus plan.
Executive Bonus Awards (2014 Performance)
| Name | Position | Bonus Amount |
|---|---|---|
| Todd C. Brady, M.D., Ph.D. | President and Chief Executive Officer | $234,000 |
| Stephen J. Tulipano | Chief Financial Officer | $44,898 |
| Scott L. Young | Chief Operating Officer | $132,300 |
Key Facts for Investor Verification
- Verify the total cash outflow impact of the $411,198 in bonuses on the company's cash position.
- Confirm the specific performance metrics used by the Compensation Committee to determine these bonus amounts.
- Review the company's most recent 10-K or 10-Q for comprehensive financial health data, as this 8-K contains no operational or financial results.